Literature DB >> 33159979

Vitamin D exerts neuroprotection via SIRT1/nrf-2/ NF-kB signaling pathways against D-galactose-induced memory impairment in adult mice.

Ammar Ali1, Shahid Ali Shah2, Nasib Zaman3, Muhammad Nazir Uddin3, Wajid Khan3, Abid Ali4, Muhammad Riaz5, Atif Kamil6.   

Abstract

Vitamin D (Vt. D) is one of the vital hormone having multiple functions in various tissues, including brain. Several evidences reported that Vt. D plays a significant part in memory and cognition as its inadequate amount may accelerate cognitive impairment. This study shows for the first time the antioxidant potential of Vt. D against D-Galactose (D-gal) induced oxidative stress mediated Alzheimer disease (AD) pathology in male adult albino mice. The result reveals that the mice exposed to D-gal (120 mg/kg) for eight weeks have pre-and post-synaptic dysfunction and impaired memory investigated through Morris water maze and Y-maze tests. This is followed by the suppressed Nuclear factor erythroid 2-related factor 2 (NRF2), Heme Oxygenase-1 (HO-1) and elevated expressions of Nuclear Factor kappa B (NF-kB), Tumor Necrosis Factor alpha (TNF-α) and Interleukin 1 beta (IL-1β) proteins in the brain homogenates evaluated through western blotting technique. On the other hand Vt. D (100 μg/kg) administration (three times a week for 4 weeks) activated Silent mating type information regulation 2 homolog 1 (SIRT1) and significantly improved both the neuronal synapse and memory, reduced oxidative stress by upregulating NRF-2 and HO-1 and downregulating NF-kB, TNF-α and IL-1β proteins expression. Most importantly, Vt. D significantly abrogate the amyloidogenic pathway of amyloid beta (Aβ) production against D-gal in the brains of adult male albino mice. These results reveal that Vt. D being an antioxidant agent plays a vital role in reducing the AD pathophysiology in D-gal induced animal model of aging, therefore act as a potential drug candidate in neurodegenerative diseases.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  D-galactose; Neuroinflammation; Oxidative stress; Vitamin D

Year:  2020        PMID: 33159979     DOI: 10.1016/j.neuint.2020.104893

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  6 in total

1.  Gastrodin From Gastrodia elata Enhances Cognitive Function and Neuroprotection of AD Mice via the Regulation of Gut Microbiota Composition and Inhibition of Neuron Inflammation.

Authors:  Opeyemi B Fasina; Jianyu Wang; Jianxia Mo; Hiroyuki Osada; Hiroshi Ohno; Wensheng Pan; Lan Xiang; Jianhua Qi
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

Review 2.  Molecular Basis Underlying the Therapeutic Potential of Vitamin D for the Treatment of Depression and Anxiety.

Authors:  Bruna R Kouba; Anderson Camargo; Joana Gil-Mohapel; Ana Lúcia S Rodrigues
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

Review 3.  Deciphering therapeutic options for neurodegenerative diseases: insights from SIRT1.

Authors:  Ruike Wang; Yingying Wu; Rundong Liu; Mengchen Liu; Qiong Li; Yue Ba; Hui Huang
Journal:  J Mol Med (Berl)       Date:  2022-03-11       Impact factor: 4.599

Review 4.  Iron dyshomeostasis and ferroptosis in Alzheimer's disease: Molecular mechanisms of cell death and novel therapeutic drugs and targets for AD.

Authors:  Yuan Zhang; Man Wang; Wenguang Chang
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988

5.  Oral administration of D-galactose increases brain tricarboxylic acid cycle enzymes activities in Wistar rats.

Authors:  Josiane Budni; Arleide Braga Brandão; Sabrina da Silva; Michelle Lima Garcez; Francielle Mina; Tatiani Bellettini-Santos; Gabriel Casagrande Zabot; Eduarda Behenck Medeiros; Giselli Scaini; Jade de Oliveira; Emílio Luiz Streck; João Quevedo
Journal:  Metab Brain Dis       Date:  2021-02-22       Impact factor: 3.584

Review 6.  The Effect of COVID-19 on NF-κB and Neurological Manifestations of Disease.

Authors:  Don A Davies; Aida Adlimoghaddam; Benedict C Albensi
Journal:  Mol Neurobiol       Date:  2021-06-01       Impact factor: 5.590

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.